4D Molecular Therapeutics Inc Dossier - Source-backed chat

4D Molecular Therapeutics Inc

FDMTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.13

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $14.31Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $790.5M

Enterprise Value $739.8M

Shares Outstanding 55.2M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

4D Molecular Therapeutics (4DMT) is a late-stage biotechnology company uniquely positioned to disrupt the multi-billion dollar retinal vascular disease market. Its lead candidate, 4D-150, leverages a proprietary customized AAV vector (R100) designed for routine, low-dose intravitreal delivery of both aflibercept and an anti-VEGF-C component. Clinical data from the PRISM Phase 1/2 trial has demonstrated best-in-class durability, safety, and a massive reduction in treatment burden (up to 90% reduction in injections). With the North American Phase 3 trial (4FRONT-1) fully enrolled ahead of schedule and a robust cash runway extending into the second half of 2028, 4DMT offers a highly asymmetric risk-reward profile for biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$17.00

Mean target$28.22

High · most bullish analyst$36.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$6.0015%

The 4FRONT-1 trial fails to demonstrate non-inferiority to aflibercept, or safety concerns emerge, such as late-onset intraocular inflammation or severe adverse events, which severely compromise 4D-150's clinical profile. Regulatory approval is delayed or denied, forcing a major restructuring. The DME and cystic fibrosis programs fail to offset the loss of the lead indication, and the company is forced to raise highly dilutive capital as its cash runway shortens.

Base CaseCentral scenario

$28.2260%

Matches the consensus mean

4D-150 meets its primary endpoint of non-inferiority in visual acuity compared to aflibercept at 52 weeks in the 4FRONT-1 trial, with topline data in H1 2027 confirming a highly competitive reduction in treatment burden and a clean safety profile. Global Phase 3 trials proceed on track, and the DME program successfully enters Phase 3 in Q3 2026. The company's cash runway remains secure into H2 2028, supported by ongoing cost-sharing with Otsuka. Valuation aligns with consensus analyst targets as clinical de-risking progresses.

Bull CaseUpside scenario

$36.0025%

4D-150 achieves superior efficacy and exceptional durability in both 4FRONT-1 and 4FRONT-2 Phase 3 trials, demonstrating near-total elimination of anti-VEGF injection burden with zero significant safety or intraocular inflammation issues. The product is rapidly approved globally, capturing a dominant share of the $20 billion retinal market. Strategic partner Otsuka successfully commercializes the therapy in the APAC region, triggering substantial milestone payments. Concurrently, the aerosol-delivered 4D-710 program for cystic fibrosis achieves breakthrough clinical efficacy in Phase 2, establishing 4DMT as a multi-platform genetic medicine powerhouse.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Highly differentiated lead asset (4D-150) targeting a massive $20 billion retinal vascular disease market with a single, routine, low-dose intravitreal injection.
Strong clinical validation from the PRISM Phase 1/2 trial showing up to 90% reduction in treatment burden and a highly favorable safety profile with up to 3.5 years of follow-up.
Robust financial position with $457.6 million in cash and marketable securities, providing a runway into the second half of 2028.
Strategic validation and risk-sharing through a major partnership with Otsuka Pharmaceutical for the APAC region, including upfront payments and clinical cost-sharing.

Key Investment Risks

Binary clinical trial risk associated with the upcoming 4FRONT-1 Phase 3 topline data readout in H1 2027.
Intense competition in the wet AMD space from established blockbuster biologics (Eylea 8mg, Vabysmo) and rival gene therapy candidates (such as Regenxbio's RGX-314).
High cash burn rate typical of late-stage clinical development, which could accelerate if global trials face delays or expansion requirements.

Thesis Invalidation Triggers

Failure of 4D-150 to meet the non-inferiority margin of 4 letters in visual acuity compared to aflibercept in the 4FRONT-1 Phase 3 trial.
Emergence of serious, recurring intraocular inflammation or other safety signals in the Phase 3 program.
Significant delays in the enrollment or initiation of the 4FRONT-2 global trial or the DME Phase 3 trial.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.